ES2623780T3 - Sistemas de expresión de baculovirus mejorados - Google Patents

Sistemas de expresión de baculovirus mejorados Download PDF

Info

Publication number
ES2623780T3
ES2623780T3 ES12745446.0T ES12745446T ES2623780T3 ES 2623780 T3 ES2623780 T3 ES 2623780T3 ES 12745446 T ES12745446 T ES 12745446T ES 2623780 T3 ES2623780 T3 ES 2623780T3
Authority
ES
Spain
Prior art keywords
baculovirus
raav
baculovirus expression
gene
expression systems
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES12745446.0T
Other languages
English (en)
Spanish (es)
Inventor
Lionel GALIBERT
Otto-Wilhelm Merten
Monique Van Oers
Christel RIVIERE
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genethon
Original Assignee
Genethon
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genethon filed Critical Genethon
Application granted granted Critical
Publication of ES2623780T3 publication Critical patent/ES2623780T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/14011—Baculoviridae
    • C12N2710/14033—Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/14011—Baculoviridae
    • C12N2710/14051—Methods of production or purification of viral material
    • C12N2710/14052—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/14011—Baculoviridae
    • C12N2710/14111—Nucleopolyhedrovirus, e.g. autographa californica nucleopolyhedrovirus
    • C12N2710/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/14144—Chimeric viral vector comprising heterologous viral elements for production of another viral vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Plant Pathology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
ES12745446.0T 2011-07-27 2012-07-27 Sistemas de expresión de baculovirus mejorados Active ES2623780T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161512142P 2011-07-27 2011-07-27
US201161512142P 2011-07-27
PCT/EP2012/064843 WO2013014294A2 (en) 2011-07-27 2012-07-27 Improved baculovirus expression systems

Publications (1)

Publication Number Publication Date
ES2623780T3 true ES2623780T3 (es) 2017-07-12

Family

ID=46640007

Family Applications (1)

Application Number Title Priority Date Filing Date
ES12745446.0T Active ES2623780T3 (es) 2011-07-27 2012-07-27 Sistemas de expresión de baculovirus mejorados

Country Status (10)

Country Link
US (1) US10480010B2 (enExample)
EP (1) EP2737071B1 (enExample)
JP (1) JP6122430B2 (enExample)
CN (1) CN103748229A (enExample)
BR (1) BR112014001863A2 (enExample)
CA (1) CA2842392C (enExample)
DK (1) DK2737071T3 (enExample)
ES (1) ES2623780T3 (enExample)
IN (1) IN2014CN00688A (enExample)
WO (1) WO2013014294A2 (enExample)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10577627B2 (en) 2014-06-09 2020-03-03 Voyager Therapeutics, Inc. Chimeric capsids
EP3215191B1 (en) 2014-11-05 2024-08-14 Voyager Therapeutics, Inc. Aadc polynucleotides for the treatment of parkinson's disease
KR20230145206A (ko) 2014-11-14 2023-10-17 보이저 테라퓨틱스, 인크. 조절성 폴리뉴클레오티드
CN114717264A (zh) 2014-11-14 2022-07-08 沃雅戈治疗公司 治疗肌萎缩性侧索硬化(als)的组合物和方法
US11697825B2 (en) 2014-12-12 2023-07-11 Voyager Therapeutics, Inc. Compositions and methods for the production of scAAV
EP3448874A4 (en) 2016-04-29 2020-04-22 Voyager Therapeutics, Inc. COMPOSITIONS FOR TREATING A DISEASE
EP3448987A4 (en) 2016-04-29 2020-05-27 Voyager Therapeutics, Inc. COMPOSITIONS FOR TREATING A DISEASE
IL297576B2 (en) 2016-05-18 2024-02-01 Voyager Therapeutics Inc Compositions and methods of treating huntington's disease
US10584337B2 (en) 2016-05-18 2020-03-10 Voyager Therapeutics, Inc. Modulatory polynucleotides
EP3831281B1 (en) 2016-08-30 2026-02-25 The Regents of The University of California Devices and systems for biomedical targeting and delivery
MX2019013172A (es) 2017-05-05 2020-09-07 Voyager Therapeutics Inc Composiciones y metodos para tratar la enfermedad de huntington.
EP3618839A4 (en) 2017-05-05 2021-06-09 Voyager Therapeutics, Inc. COMPOSITIONS AND METHODS OF TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS (ALS)
JOP20190269A1 (ar) 2017-06-15 2019-11-20 Voyager Therapeutics Inc بولي نوكليوتيدات aadc لعلاج مرض باركنسون
CA3070087A1 (en) 2017-07-17 2019-01-24 Voyager Therapeutics, Inc. Trajectory array guide system
US11512327B2 (en) 2017-08-03 2022-11-29 Voyager Therapeutics, Inc. Compositions and methods for delivery of AAV
MX2020003042A (es) 2017-09-29 2020-11-18 Voyager Therapeutics Inc Rescate del fenotipo neurológico central y periférico de la ataxia de friedreich mediante administración intravenosa.
WO2019079242A1 (en) 2017-10-16 2019-04-25 Voyager Therapeutics, Inc. TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS (ALS)
TW202413649A (zh) 2017-10-16 2024-04-01 美商航海家醫療公司 肌萎縮性脊髓側索硬化症(als)之治療
CN112424359A (zh) 2018-05-15 2021-02-26 沃雅戈治疗公司 用于治疗帕金森氏病的组合物和方法
US12281321B2 (en) 2018-09-28 2025-04-22 Voyager Therapeutics, Inc. Frataxin expression constructs having engineered promoters and methods of use thereof
AU2019354793A1 (en) * 2018-10-05 2021-05-13 Voyager Therapeutics, Inc. Engineered nucleic acid constructs encoding AAV production proteins
WO2020081490A1 (en) * 2018-10-15 2020-04-23 Voyager Therapeutics, Inc. EXPRESSION VECTORS FOR LARGE-SCALE PRODUCTION OF rAAV IN THE BACULOVIRUS/Sf9 SYSTEM
CN109609552B (zh) * 2018-12-28 2020-04-14 中国科学院武汉物理与数学研究所 重组腺相关病毒的制备方法、系统及重组杆粒
KR20210126096A (ko) 2019-02-15 2021-10-19 상가모 테라퓨틱스, 인코포레이티드 재조합 aav를 제조하기 위한 조성물 및 방법
KR102272651B1 (ko) * 2019-03-28 2021-07-02 충북대학교 산학협력단 외래단백질의 발현량과 발현시간이 증대된 배큘로바이러스
WO2020264139A1 (en) * 2019-06-26 2020-12-30 Virovek, Inc. Baculovirus expression system
US20220154223A1 (en) 2020-10-15 2022-05-19 Hoffmann-La Roche Inc. Nucleic acid constructs for simultaneous gene activation
CN114317608B (zh) * 2020-12-28 2023-08-22 陕西杆粒生物科技有限公司 一种基因敲除型杆状病毒表达载体
CN117716044A (zh) * 2021-07-28 2024-03-15 生物马林药物股份有限公司 大规模腺相关病毒生产系统

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4745051A (en) 1983-05-27 1988-05-17 The Texas A&M University System Method for producing a recombinant baculovirus expression vector
EP0127839B1 (en) 1983-05-27 1992-07-15 THE TEXAS A&M UNIVERSITY SYSTEM Method for producing a recombinant baculovirus expression vector
DK518384A (da) 1984-01-31 1985-07-01 Idaho Res Found Vektor til fremstilling af et gen-produkt i insektceller, fremgangsmaade til dens fremstilling samt dens anvendelse
FR2664905B1 (fr) * 1990-07-18 1994-08-12 Agronomique Inst Nat Rech Baculovirus modifie, son procede d'obtention, et vecteurs d'expression obtenus a partir dudit baculovirus.
CN1205741A (zh) * 1995-12-22 1999-01-20 纳幕尔杜邦公司 重组杆状病毒的生产

Also Published As

Publication number Publication date
US20140356904A1 (en) 2014-12-04
CA2842392A1 (en) 2013-01-31
EP2737071B1 (en) 2017-03-15
BR112014001863A2 (pt) 2017-02-21
JP6122430B2 (ja) 2017-04-26
DK2737071T3 (en) 2017-05-08
CA2842392C (en) 2020-09-15
EP2737071A2 (en) 2014-06-04
WO2013014294A3 (en) 2013-04-04
CN103748229A (zh) 2014-04-23
WO2013014294A2 (en) 2013-01-31
IN2014CN00688A (enExample) 2015-04-03
US10480010B2 (en) 2019-11-19
JP2014522658A (ja) 2014-09-08

Similar Documents

Publication Publication Date Title
JP6122430B2 (ja) 改善されたバキュロウイルス発現系
RU2739596C2 (ru) Продуцирование aav в клетках насекомых, способы и композиции для этого
JP7595371B2 (ja) トリコプルシア・ニの蛹における組み換えタンパク質の発現
ES2787706T3 (es) Producción de productos biofarmacéuticos a base de baculovirus sin viriones baculovíricos contaminantes
CN106459984B (zh) 昆虫细胞中产生的进一步改善的aav载体
JP2009195237A5 (enExample)
CN1343257A (zh) 基于重组猪腺病毒的病毒载体和病毒疫苗
EP4079861A1 (en) Preparation method and system for recombinant adeno-associated virus and recombinant bacmid
CN106987603B (zh) 一种重组腺相关病毒的制备方法
CN106544325A (zh) 一种重组杆状病毒及其应用
TW202028468A (zh) 用於桿狀病毒/Sf9系統中rAAV之大規模生產的表現載體
US20240374706A1 (en) Fmdv virus-like particle with double stabilizing mutation
WO2020133772A1 (zh) 重组腺相关病毒的制备方法、系统及重组杆粒
Li et al. Subunit vaccine of PCV3 capsid protein produced by sf9 cells with double knockout of Caspase-1 and Dronc induces strong immune response in mice
Nakanishi et al. Comparative studies of lepidopteran baculovirus-specific protein FP25K: development of a novel Bombyx mori nucleopolyhedrovirus-based vector with a modified fp25K gene
CN105392362B (zh) 用于在宿主昆虫中表达重组蛋白的杆状病毒dna元件
CN102304529B (zh) 一种兔出血热病毒空衣壳抗原的制备方法
JP2025533550A (ja) Aav遺伝子治療ベクターによる心筋症の治療
CN104403006A (zh) 水貂细小病毒病毒样颗粒及其制备方法与应用
KR20240049581A (ko) 구제역 바이러스 바이러스-유사 입자의 생성 방법
TW202246515A (zh) 富含組胺酸之肽作為轉染試劑用於產生rAAV及rBV之用途
CN121271808A (zh) 一种生产低空壳率腺相关病毒的重组杆状病毒及其应用
Su et al. A novel method for construction of baculovirus bacmids
CN120210289A (zh) 重组杆状病毒转移载体及其制备方法和应用
KR20240046569A (ko) 구제역 바이러스 바이러스-유사 입자의 생성 방법